PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Hepatology. Author manuscript; available in PMC 2013 September 3.
Published in final edited form as:
PMCID: PMC3760215
NIHMSID: NIHMS317500

A Polymorphism that Delays Fibrosis in Hepatitis C Promotes Alternative Splicing of AZIN1, Reducing Fibrogenesis

Abstract

Among several single nucleotide polymorphisms (SNPs) that correlate with fibrosis progression in chronic HCV, a SNP in the antizyme inhibitor (AzI) gene is most strongly associated with slow fibrosis progression. Our aim was to identify the mechanism(s) underlying this observation by exploring the impact of the AzI SNP on hepatic stellate cell (HSC) activity. Seven novel AZIN1 splice variants (“SV2-8”) were PCR-cloned from the LX2 human HSC line. Expression of a minigene in LX2 containing the AZIN1 slow-fibrosis SNP yielded a 1.67 fold increase in AZIN1 splice variant 2 (AZIN1 SV2) mRNA (p= 0.05). In healthy human leukocytes, the SNP variant also correlated with significantly increased SV2 mRNA. Cells (293T) transfected with shRNA complementary to the exonic splicing chaperone SRp40 expressed 30% less SRp40 (p = 0.044) and 43% more AzI SV2 (p = 0.021) than control shRNA-expressing cells, mimicking the effect of the sequence variant. LX2 cells transfected with AZIN1 full-length cDNA expressed 35% less collagen I mRNA (p = 0.09) and 18% less SMA mRNA (p=0.09). Transient transfection of AZIN1 SV2 cDNA into LX2 cells reduced collagen I gene expression by 64% (p = 0.001) and αSMA by 43% (p = 0.005) compared to vector-transfected controls, paralleling changes in protein expression. Both AZIN1 and AZIN-SV2 mRNAs are detectable in normal human liver and reduced in HCV cirrhotic livers. The AZIN1-SV2 acts via a polyamine-independent pathway, as it neither interacts with antizyme nor affects the ability of AZIN1 lacking this variant to neutralize antizyme.

Conclusions

A SNP variant in the AZIN1 gene leads to enhanced generation of a novel alternative splice form that modifies the fibrogenic potential of HSCs.

Keywords: Stellate Cells, Alternative Splicing, Antizyme Inhibitor 1, Polyamines

Introduction

Hepatic fibrosis, or accumulation of interstitial ‘scar’ matrix, can occur in response to many hepatic injuries. Cirrhosis is the end-stage of fibrosis, and is characterized by septal scar encircling nodules of hepatocytes (1). ‘Activation’ of HSCs into a myofibroblast-like cell is a hallmark of fibrotic liver disease, and is characterized by the induction of fibrogenic and proliferative cytokines, as well as enhanced deposition of interstitial or ‘scar’ extracellular matrix (ECM), especially collagen I. The myofibroblast is the major source of fibrosis in injured liver (2). Sustained or chronic liver injury accelerates the accumulation of these α smooth muscle actin-expressing myofibroblasts, whose deposition of ECM disrupts normal liver structure and function (3).

Chronic hepatitis C (CHC) is the most common cause of cirrhosis and the leading indication for liver transplantation in the United States and Western Europe. The rate of progression from fibrosis to cirrhosis varies widely amongst patients with CHC, such that some patients harbor HCV for decades with minimal scarring, whereas others can progress in a decade or less to cirrhosis and liver failure (4). While definable factors including alcohol, age, and obesity (5) may contribute to some of the accelerated risk, host genetic factors are increasingly recognized to affect the rate of fibrosis progression. Recently, large-scale studies using whole genome analysis have sought the genetic risk factors involved in complex disease, as well as host factors involved in pathological consequences of viral infections by identifying single nucleotide polymorphisms (SNPs) that correlate with specific disease or treatment outcomes. As expected for the hypothesis-independent nature of these genetic association studies – including several of the risk-associated SNPs of a reported cirrhosis risk score (1) - the mechanisms underlying the role of each SNP remain unclear. Following re-sequencing of implicated genes and fine-mapping, the original risk score SNPs appear to be the most strongly associated variants (6), removing the ambiguity of possible linkage to genetic variants in nearby genes. Moreover, whereas the original cirrhosis risk score was derived from a cross sectional study, the score has now been validated in two separate, prospective studies (7), (8).

We sought to determine the functional involvement of a highly protective single nucleotide polymorphism (SNP) variant in the AZIN1 gene (1). This SNP is a synonymous (tyrosine) coding substitution in AZIN1. This allelic SNP variant is found as the minor allele in Caucasians and is rarely present in African Americans and Asians.

AZIN1 is expressed in liver (9) and promotes cell growth and proliferation by increasing intracellular polyamine levels and stabilizing cyclin D1 (10, 11). Polyamines are organic cations that regulate fundamental cellular processes, especially cellular proliferation (12). Ornithine decarboxylase (ODC) is the first and rate-limiting enzyme in the biosynthesis of polyamines. ODC is a short-lived, highly regulated, enzyme subject to autoregulation by polyamines (13, 14). In the center of this autoregulatory circuit is a small polyamine-induced protein named antizyme (Az), which promotes ubiquitin-independent degradation of ODC and inhibits cellular uptake of polyamines. Az itself is regulated by the ODC-related protein antizyme inhibitor (AZIN1), which titrates intracellular polyamine levels by antagonizing Az function, allowing ODC to escape Az-mediated degradation and stimulate cellular polyamine uptake.

The proteomic complexity derived from a relatively small number of genes has been ascribed in large measure to pre-mRNA alternative splicing, which allows a single gene to produce multiple proteins (15). Coding-region SNPs may exert phenotypic variability by modifying pre-mRNA splicing accuracy or efficiency (16). Exonic cis-elements contain RNA sequences that bind exonic splicing enhancers (ESE), proteins that promote exon definition by direct recruitment of the splicing machinery via their serine/arginine-rich (SR) regions or by antagonizing nearby silencing elements (17). Single nucleotide polymorphisms can create or ablate known ESE binding regions, thereby affecting the outcome of pre-mRNA processing.

The recognized primary transcript of AZIN1 encodes a functional 448 amino-acid protein. Given the location of the SNP relative to the 5′ intron/exon border of the twelfth exon, we speculated that it might affect AZIN1 pre-mRNA splicing. SRp40 is an ESE that binds to specific exonic cis-element and chaperones the formation of the spliceosomal subunits (18). Its expression is up-regulated during liver regeneration (19). Therefore, we hypothesized that the silent SNP associated clinically with slower rates of hepatic fibrosis alters the splicing pattern of AZIN1 pre-mRNA to favor the expression of a variant protein that would suppress the fibrogenicity of HSCs.

Methods

Semi-quantitative PCR and Sequencing to Identify Splice Variants

PCR was performed using AZIN1 forward 5′-ACAGTGAAGTGCAACTCTGCTCCA-3′ and AZIN1 reverse 5′-TGGGCTTCCATCTCCACTAAGTCA-3′ with LX2 complementary DNA (cDNA) as a template. The reaction products were separated using gel electrophoresis. Bands were extracted using the QIAquick® Gel Extraction Kit (Qiagen, Chatsworth, CA). The DNA fragments were then cloned into the pcDNA3.1/V5-His© TOPO© TA Expression Kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Inserts were sequenced using the T7 forward and BGH reverse priming sites.

AZIN1 Minigene and Site Directed Mutagenesis

PCR was performed using AZIN1 minigene forward 5′-TGCTCCTCCTGCTCTCTGATGTTT-3′ and AZIN1 minigene reverse 5′-CCAAGGGCAATTTGATGGCAATGG-3′ with genomic DNA from LX2 cells as a template. The products of the reaction were separated using gel electrophoresis. Bands were excised and extracted using the QIAquick® Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol. The DNA was then cloned into the pcDNA3.1/V5-His© TOPO© TA Expression Kit (Invitrogen,) according to the manufacturer’s protocol. The SNP was introduced using the QuickChange® II XL Site Directed Mutagenesis Kit (Stratagene, LaJolla, CA) according to the manufacturer’s protocol using the following primers: AZIN1 SNP forward 5′-cCAGAGGTTCACAAGGCAAAAATATAAGGAAGATGAGC-3′ and AZIN1 SNP reverse 5′-GCTCATCTTCCTTATATTTTTGCCTTGTGAACCTCTGG-3′.

AZIN1 WT and SV2 Expression Vectors and SRp40 ShRNA

PCR was performed using the following primers: AZIN1 WT/SV2 forward 5′-GGCTTTGTGGAATACGGCTGAGATG-3′, AZIN1 WT reverse 5′-GATCTAAAGAAGCGTTAATGCCTG-3′ and AZIN1 SV2 reverse 5′-CTTCAGCGGAAAAGCTCATCACAG-3′ with cDNA from LX2 cells as a template. The products were subjected to gel electrophoresis with a 2% agarose gel. Bands were excised and extracted using the QIAquick® Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol. The DNA was then cloned into the pcDNA3.1/V5-His© TOPO© TA Expression Kit (Intivtrogen) according to the manufacturer’s protocol. Four clones with shRNA targeting SRp40 and their control (Origene, Rockville, MD, # TG309487) were tested for their ability to reduce expression of SRp40 mRNA. These studies are based on the shSRp40 sequence 5′-GTTGAGAATTTATCCTCAAGAGTCAGCTG-3′. Transient transfection of these clones and gene assessment was performed as described below.

RNA and Quantitative Real-time PCR Analysis

RNA was extracted from cells overexpressing either LacZ, AZIN1 WT, AZIN1 SV2, shSRp40 or shC using the RNeasy® Mini Kit (Qiagen). All RNA was treated with DNAse (Roche). A total of 1 μg of RNA per condition was reverse transcribed with first strand cDNA synthesis with random primers using Sprint™ RT Complete-Double PrePrimed tubes (Clontech, Mountain View, CA). Quantitative real-time (RT-PCR) was performed using the following primers on a LightCycler® 480 (Roche): AZIN1 SV2 forward 5′-CGGAAGTGATGAACCAGCCTTCATGT-3′ and AZIN1 SV2 reverse 5′-GCTTCAGCGGAAAAGCTCAT-3′; AZIN1 WT F 5′-GAAAGCTGTCTTCTTCCTGAGCTG -3′ and AZIN1 WT R 5′-GGTTCATGGAAAGAATCTGCTCCCA -3′ AZIN1 SV8 forwad 5′-CAGAACCCGGAAGCTACTATGTGT-3′ and AZIN1 SV8 reverse 5′-TGTAATAAATGGCTGGCCTCTTGTG-3′ αSMA forward 5′-AGGCACCCCTGAACCCCAA-3′ and αSMA reverse 5′-CAGCACCGCCTGGATAGCC-3′; collagen I forward 5′-GGCTTCCCTGGTCTTCCTGG-3′ and collagen I reverse 5′-CCAGGGGGTCCAGCCAAT-3′; GAPDH forward 5′-CAATGACCCCTTCATTGACC-3′ and GAPDH reverse 5′-GATCTCGCTCCTGGAAGATG-3′. All experiments were done in triplicate and normalized to GAPDH. Cycle numbers (CT) for AZIN1 isoform mRNA detection were: AZIN1 - 24.1; SV1 - 32.6; SV2 - 28.3; SV7 - 27.7.

Patient Samples

Blood specimens from normal donors at Blood Centers of the Pacific were collected in EDTA and Paxgene tubes. Genomic DNA was isolated from the EDTA tubes using the QIAmp Extraction kit (Qiagen) and RNA was isolated from the PAXgene tubes using the PAXgene Blood RNA kit (Qiagen). All samples were de-identified and unlinked from the donor. IRB approval was obtained from the UCSF Committee on Human Research.

Human liver tissue samples

A total of 10 human liver samples obtained either from liver resection or transplantation were analyzed. All samples were obtained from the HCC Genomic Consortium: Mount Sinai School of Medicine, NY (US), Hospital Clinic, Barcelona (Spain) and Istituto Nazionale dei Tumori, Milan (Italy). Laboratory techniques were performed in the laboratories of the Division of Liver Disease at the Mount Sinai School of Medicine. The research protocol was approved by the institutional review boards, and informed consent was obtained in all cases. 5 samples were obtained from a non-tumor carrying liver lobe of patients undergoing liver resection or transplantation for HCC on the background of HCV cirrhosis. Results were compared with samples of normal tissue obtained from 5 patients undergoing liver resection for non-malignant lesions [hepatic haemangioma (2 patients), focal nodular hyperplasia (2 patients), complicated cyst (1 patient)]. A detailed description of tissue collection and RNA extraction from liver samples is detailed elsewhere (20) (21).

Genotyping

The AZIN1 hCV25635059 polymorphism was genotyped by PCR using allele-specific primers (5′-AACAGAGGCTCATCTTCCTTA-3′ or 5′-ACAGAGGCTCATCTTCCTTG-3′ and 5′-TGAGCACATTGGATCTGAGACAG-3′). Approximately 3 ng of DNA was amplified with 5 units AmpliTaq Gold in a buffer containing 15 mM Tris pH 8.0, 2.5 mM MgCl2, 50 mM KCl, 200 μM dAGC and 400 μM dUTP, 2 units of uracil-N-glycosylase (UNG), 1X ROX, and 0.2X SYBR green. The reactions were amplified on the ABI Prism 7500 as follows: 50°C for 2 min, 95°C for 10 min, followed by 45 cycles of 15 sec at 95°C and 1 min at 60°C.

AZIN1 Splice Variant Expression Analysis

Total RNA was reverse transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Norwalk, CT) with random hexamers. The transcription levels of total AZIN1 and the AZIN1 SV2 were quantified by real-time quantitative PCR using a primer set that amplifies all variants of AZIN1: total forward 5′-GCTTGCAAAGAATCTCAAGTATA-3′ and AZIN1 total reverse 5′-GTTCCCGTGAATCCTCCACCA-3′ and a primer set that is specific for SV2 (see above). Five ng of cDNA was used for quantification of total AZIN1 and 20 ng for SV2. A dilution series of LX2-LACZ cDNA (2.5 pg to 25 ng) was amplified with each primer set and the cycle thresholds (Cts) used to generate a standard curve. The abundance of total AZIN1 WT and AZIN1 SV2 in each sample was determined by extrapolating the Cts of the respective standard curves. The amount of AZIN1 SV2 relative to total AZIN1 was determined by measuring the ratio of AZIN1 SV2 to total AZIN1.

Cell Culture and Transient Transfection

LX2 and 293FT cells were plated in six-well dishes and serum starved for four hours prior to transfection. Cells were transiently transfected using the Lipofectamine™ 2000 (Invitrogen) in DMEM containing 0.2% bovine serum albumin. Human embryo kidney cells (293 HEK) were transiently transfected by the calcium phosphate method(22).

Western Blot

LX2 cells grown in 6-well dishes were transfected with 2 μg of DNA/well of LacZ, AZIN1-WT or AZIN1-SV2 encoding cDNAs. Cell extracts for Western blotting were harvested in the Complete-Lysis M buffer (Roche) 48 hours after transfection. Equal amounts of protein (25 μg), as determined by the Bio-Rad DC protein quantification assay, were loaded and separated by PAGE and transferred to PVDF membranes. Western blotting was performed using rabbit polyclonal antibodies to αSMA (Abcam) and collagen I (Rockland). Other immunoblots were carried out as follows: cellular extracts were prepared by lysis of cells in lysis buffer (50 mM Tris-Hcl, pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, and 1 mg/ml each of leupeptin, aprotinin, and pepstatin). Insoluble material was removed by centrifugation. Equal amounts of protein were mixed with Laemmli sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, and 0.123 M Tris-HCl, pH 6.8), heated for 5 minutes at 95°C and fractionated by electrophoresis in polyacrylamide-SDS gel. The resolved proteins were electroblotted onto a nitrocellulose membrane. The membrane was incubated with the indicated antibodies followed by horseradish peroxidase-conjugated anti IgG antibodies. The antibodies used were mouse monoclonal anti-FLAG (Sigma) and rabbit polyclonal anti-Az(23). Signals were developed using ‘EZ-ECL’ (Biological Industries) and the membranes were exposed to x-ray film and developed.

Co-immunoprecipitation

Co-immunoprecipitation experiments were carried out with extracts from cells transiently co-transfected with Flag-tagged human AZIN1 or AZIN1 SV2 and Az. The reactions were incubated overnight with anti-Flag beads (Sigma). The immunoprecipitated material was resolved by electrophoresis in an SDS-polyacrylamide gel and the proteins were visualized using anti-Flag or anti-Az antibodies, following electroblotting onto nitrocellulose.

Degradation Assay

Protein synthesis was inhibited by the addition of cycloheximide (20 μg/ml) to the growth medium of transiently transfected cells, either alone or together with the proteasome inhibitor MG132, and harvested at the indicated times. Cells were lysed and aliquots containing equal amounts of protein were fractionated by SDS-PAGE and examined by Western blot.

ODC Activity Assay

ODC activity assay was performed as previously described(24). 100 μg aliquots of cellular extracts were mixed with 100 μl of ODC buffer (25 mM Tris-HCl pH 7.5, 2.5 mM DTT, 0.1 mM EDTA, 0.2 mM pyridoxal phosphate, 0.33 mM L-ornithine), containing 0.5 μCi L-[14C] ornithine. The reaction mix was incubated at 37°C in a 96-well plate for 4 hours. The liberated [14C]-CO2 was trapped in a covering 3 mm paper soaked with saturated barium hydroxide solution. The paper was washed with acetone, dried and the results quantified using the Fuji Bas2500 phosphoimager.

Results

AZIN1 mRNA is alternatively spliced

The location of the AZIN1 SNP, six nucleotides from the 5′ splice-site of the twelfth exon, suggested that the SNP could affect splicing of AZIN1 pre-mRNA. Furthermore, analysis of the AZIN1 genomic sequence, using the ESEFinder 2.0 software (25), predicted decreased binding of the exonic splicing enhancer, SRp40, to the SNP containing sequence by affecting regional splice-site recognition. Review of AZIN1 transcripts in the RefSeq database (26) (www.genome.ucsc.edu) revealed one AZIN1 splice variant that reportedly alters the transcript in the 5′ untranslated region. A shotgun analysis, performed as part of the sequencing of the human genome (27), had previously revealed one variant, termed here as ‘AZIN1 SV1,’ that includes intron 11. To determine if there are additional AZIN1 splice variants, we performed PCR on cDNA from a cultured human stellate cell line (LX2) using primers targeting AZIN1’s 5′ and 3′ non-coding regions. The resulting amplicons were separated by agarose gel electrophoresis (Figure 1A), extracted and sequenced. In total, seven novel AZIN1 splice variants, termed AZIN1 SV2-8, were detected (Figure 1B).

Figure 1
AZIN1 mRNA is alternatively spliced

The fibrosis-protective SNP in AZIN1 increases mRNA alternative splicing in vitro and in vivo

The presence of the protective SNP variant predicts an increased likelihood of AZIN1 mRNA alternative splicing based on analysis using the ESE finder software (25). Specifically, the G to A polymorphism, located six nucleotides from an intron-exon boundary, abolished a high scoring (4.3949) SRp40 binding motif (Figure 2A). To test whether this variant altered the propensity for the native AZIN1 mRNA to undergo alternative splicing, we generated two ~4 Kbp mini-genes spanning the middle of the tenth exon to the middle of the thirteenth exon (corresponds to the genomic sequence in Figure 1B). One minigene contained the major allele nucleotide, at bp 1,345, the other contained the protective minor allele, T. Relative production of AZIN1 splice forms was then quantified by real-time quantitative PCR. Minigenes, rather than the full genomic locus, were used because the latter is 37.8 Kbp, which cannot be reliably transfected and expressed in LX2 cells. Indeed, LX2 cells transfected with the SNP-containing minigene expressed 1.67 fold (p = 0.05) more AZIN1 SV2 mRNA than cells transfected with a minigene containing the major allelic sequence, a biologically meaningful increase given that this increased expression reflects of a germline sequence change rather than mutation (Figure 1C). AZIN1 SV2 encodes a truncated, 362 amino acid (AA) protein that involves the loss of 87 and gain of 2 amino acids at the AZIN1 C-terminus.

Figure 2
The AZIN1 SNP transcript eliminates an SRp40 binding site, which regulates AZIN1 splicing and increases AZIN1 SV2

We next examined whether the presence of the variant altered the relative expression of AZIN1 splice forms in humans by comparing splice form expression using real time PCR in leukocytes from healthy donors with homozygous expression of the major allele sequence, to those with heterozygous expression. We were only able to detect meaningful expression of AZIN1 SV1, SV2, and SV7 (Table S1). In agreement with the mini-gene experiments in cultured cells, leukocytes from heterozygous patients (Table 1) with one copy of the protective SNP variant-containing sequence had a significantly higher ratio of AZIN1 SV2 to AZIN1 (17.9220), than patients homozygous for the major allele sequence, 13.6782 (p = 0.0022) (Figure 1D). In contrast, there were no significant differences in expression of other splice variants (Table S1). Even though there were more males in the homozygous group, we did not detect a correlation between relative AZIN1 SV2 expression and gender (Table S2).

Table 1
PBMC donor demographics

Loss of SRp40 binding increases expression of AZIN1 SV2

Computer analysis suggested that the introduction of the SNP variant to the AZIN1 sequence would significantly decrease the binding of SRp40 (Figure 2A), an exonic binding enhancer, whose expression is increased during liver regeneration. To mimic the loss of SRp40 binding, we compared mRNA expression of AZIN1 and AZIN1 SV2 in cells expressing shRNA against SRp40 to cells expressing a control shRNA (shC). Thirty-six hours after transient transfection, we observed a 30% (p = 0.04) decrease in SRp40 expression and a 43% (p = 0.02) increase in AZIN1 SV2 expression in 293FT cells transfected with shSRp40 relative to cells transfected with shC (Figure 2B). This suggests that the increased AZIN1 SV2 expression observed in patients harboring the SNP variant is mediated by loss of SRp40 binding.

AZIN1 SV2 inhibits expression of fibrogenic genes

We examined if the increased generation of AZIN1 SV2 conferred by the fibrosis-protective SNP inhibited fibrogenic gene expression by stellate cells. To do so, LX2 cells were transiently transfected with either LacZ, AZIN1 WT or AZIN1 SV2 cDNAs and expression of collagen I and α smooth muscle actin mRNAs was assessed using real-time PCR. Expression of AZIN1 WT reduced collagen I and α smooth muscle actin mRNAs by 35.5% and 18.2% respectively (p = 0.089 for both genes), relative to LacZ-transfected cells. AZIN1 SV2 more significantly suppressed gene expression of collagen I and α smooth muscle actin mRNAs by an additional 64.1% (p = 0.001) and 42.6% (p = 0.005), respectively (Figures 3A and 3B). Furthermore, LX2 cells expressing AZIN1 SV2 expressed 41.1% less collagen I (p = 0.0036) and 29.9% less α smooth muscle actin (p = 0.017) and LX2 cells expressing AZIN1 WT (Figures 3A and 3B). These mRNA findings were correlated with parallel changes in protein expression by Western blot (Figure 3C). To confirm that the AZIN isoforms are expressed in human liver, we performed real time PCR of AZIN1 WT and SV2 in both normal and cirrhotic whole liver mRNA, documenting their expression (Figure 3D). Interestingly, expression of both isoforms decreased significantly in cirrhotic tissues, the significance of which is unclear, since the cellular sources of these mRNAs are not defined.

Figure 3
AZIN1 SV2 transfection inhibits expression of fibrogenic genes in hepatic stellate cells

AZIN1 SV2 functions via a polyamine-independent pathway

Because the main function of AZIN1 is to regulate the degradation of ODC and the uptake of polyamines by neutralizing antizyme, we examined whether AZIN1 SV2 affects the cellular polyamine metabolism. Co-immunoprecipitation using transfected FLAG-tagged AZIN1 and SV2 in 293T cells was performed to examine the relative affinity of AZIN1 and AZIN1 SV2 for antizyme. As shown in Figure 4A, while wild-type AZIN1 without this variant interacts efficiently with antizyme, there was no interaction between AZIN1 SV2 and antizyme. Cycloheximide chase demonstrated that the half-life of AZIN1 SV2 is markedly shorter than that of the wild-type AZIN1 protein lacking this variant (Figure 4B), reflecting the lack of interaction with Az that stabilizes the protein (28). In contrast to AZIN1, and in agreement with its inability to bind Az, AZIN1 SV2 failed to stimulate ODC activity in transfected cells (Figure 4C). Moreover, when co-expressed, AZIN1-SV2 did not interfere with the ability of AZIN1 to stimulate ODC activity (Figure 4D).

Figure 4
AZIN1 SV2 functions via a polyamine-Independent pathway

Discussion

Patients with chronic hepatitis C (CHC), the leading cause of cirrhosis in the United States and Western Europe, accumulate fibrosis at highly variable rates. A gene-centric functional genome single nucleotide polymorphism (SNP) scan that sought to characterize the genetic risk factors of fibrosis progression identified a SNP in the Antizyme Inhibitor (AZIN1) gene. The SNP in this gene had the most robust cross-validation score in the first step in the development of the multi-SNP score, as well as the highest odds ratio amongst the predictive SNPs correlating with delayed fibrosis progression (1). However, like several of the risk-associated SNPs that emerged from this and other genetic association studies, the mechanism underlying this gene’s involvement and the specific protective effect of the minor allelic SNP variant remain to be clarified. Recently, studies from our laboratory have established mechanisms underlying effects of additional SNP variants of the TLR4 (29), another gene included in the cirrhosis risk score, and DDX5 (30), a separately reported gene on fibrogenic activities of HSCs, both of which were identified from the same genetic scan.

The AZIN 1 SNP encodes a silent polymorphism that does not alter the primary protein sequence. However, the SNP’s proximity to an intron-exon boundary led us to hypothesize that the SNP altered the splicing of AZIN1 pre-mRNA, and computational analysis of the exonic sequence surrounding the SNP predicted decreased binding of an exonic splicing enhancer. Indeed, we have identified eight AZIN1 splice variants that are proximal to C-terminus of the AZIN1 protein, suggesting that the SNP resides in a region of alternative splicing.

To assess the impact of the SNP variant on alternative splicing, we generated partial AZIN1 minigenes containing the two allelic SNP nucleotides. Quantitative RT-PCR demonstrated significant increases in AZIN1 SV2 and AZIN1 SV8 (Figure S1). The increase in SV2 and SV8 was unexpected because while the SNP is located six nucleotides from the 5′ end of exon 12, it appeared to have the greatest influence on 3′ splice site recognition.

We have established the in vivo relevance of the HSC culture findings by demonstrating that the fibrosis-protective variant is correlated with the increased expression of the SV2 mRNA splice form in leukocytes from healthy patients whose genomic DNA contains at least one copy of this SNP variant. While evidence of increased splicing in liver-derived cells rather than leukocytes would be more informative, there were insufficient numbers of liver samples containing the minor allelic variant to perform such an analysis. Nonetheless, we have been able to establish that both isoforms are expressed in normal human liver. However, because HSCs, the fibrogenic cell in liver, represent only a small percentage of resident liver cells, our analysis of whole-liver mRNA likely reflects expression primarily in hepatocytes rather than in cells where the SNP regulates fibrogenic gene expression.

Prior studies have demonstrated that polyamines, whose synthesis is promoted by AZIN1, play an essential role in hepatocellular regeneration following partial hepatectomy or toxic liver injury (31-33). Our study did not detect an AZIN1 splice form perturbation of polyamine content. Interestingly, AZIN1 knockout mice, which die at birth, have non-specific liver abnormalities but otherwise normal tissues, suggesting that AZIN1 is essential for normal liver development, architecture or function (9). It is unknown whether these liver abnormalities are independent of polyamine content, but the question merits reassessment in light of the results described here.

Because the AZIN1 SNP variant correlates with a slower rate of fibrosis and leads to increased AZIN1 SV2, we characterized the effects of the two allelic variants of AZIN1 in the hepatic stellate cell, which is the cellular effector of fibrosis. Moreover, AZIN1 has not previously been characterized in any fibrogenic cell type. Over-expression of AZIN1 SV2 significantly inhibited expression of αSMA and collagen I mRNAs and proteins. While AZIN1 moderately reduced fibrogenic gene expression in stellate cells following transfection, the inhibition was markedly increased in the presence of AZIN1 SV2, suggesting that AZIN1 SV2 exerts a unique affect on stellate cell responses.

The specific inhibition of genes characteristic of activated HSCs by AZIN1 SV2 was polyamine-independent, as described above. AZIN1 SV2 does not interact with Az based on co-immunoprecipitation, and it does not interfere with the ability of AZIN1 to neutralize Az activity, excluding the possibility that AZIN1 SV2 functions as a dominant negative protein. Accordingly, ODC activity was unaffected by over-expression of AZIN1 SV2. This finding was surprising, as the AZIN1 SV2 protein conserves the known Az binding site, suggesting that the interaction between AZIN1 and Az may require inclusion of sequences from the C-terminal part of the AZIN1 protein for proper tertiary structure and interaction with Az.

Polyamine biology and biosynthetic pathways have proven a target-rich arena for therapeutic intervention with cancer as a primary and hyperproliferative disorders as a secondary disease focus (34). Even though clinical success for these strategies has proven evasive, recruitment of the developed antagonists merit study for liver fibrosis given the implicated role of the AZIN1.

In summary, the minor allelic SNP variant in the twelfth exon of AZIN1 associated with slower rates of fibrosis progression favors the expression of a novel splice form, AZIN1 SV2, that inhibits the expression of fibrogenic genes in hepatic stellate cells via a novel, polyamine-independent pathway.

Supplementary Material

Supp Figure S1

Supp Table S1

Supp Table S2

Supplementary Legends

Acknowledgements

The authors gratefully acknowledge the assistance of Michael Busch, M.D. of Blood Centers of the Pacific for acquisition of patient blood samples, and Johnny Loke for technical assistance with real time PCR and shRNA studies.

Grant Support: The work was supported by Celera (to SLF) and NIH grant RO1 DK56621 (to SLF), the Israel Science Foundation (to CK), and by a grant from the Deutsche Forschungsgemeinschaft (to PK). Andrew Paris was supported by a Doris Duke Clinical Research Fellowship and an Alpha Omega Alpha Student Research Fellowship.

Abbreviations

(Az)
Antizyme
(AzI)
antizyme inhibitor
(CHC)
chronic Hepatitis C
(HCC)
hepatocellular carcinoma
(HCV)
Hepatitis C Virus
(Col I)
collagen I
(ECM)
extracellular matrix
(HSC)
Hepatic Stellate Cell
(ODC)
ornithine decarboxylase
(SNP)
single nucleotide polymorphism
(SMA)
smooth muscle actin
(SV)
splice variant
(shRNA)
short hairpin RNA

References

1. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, Rowland CM, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007;46:297–306. [PubMed]
2. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–1669. [PMC free article] [PubMed]
3. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247–2250. [PubMed]
4. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832. [PubMed]
5. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut. 2003;52:574–579. [PMC free article] [PubMed]
6. Li Y, Chang M, Abar O, Garcia V, Rowland C, Catanese J, Ross D, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol. 2009;51:750–757. [PMC free article] [PubMed]
7. Pradat P, Trepo E, Potthoff A, Bakshi R, Young B, Trepo C, Lagier R, et al. The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 51:356–357. [PubMed]
8. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, Sebastiani G, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2009;50:1038–1044. [PubMed]
9. Tang H, Ariki K, Ohkido M, Murakami Y, Matsufuji S, Li Z, Yamamura K. Role of ornithine decarboxylase antizyme inhibitor in vivo. Genes Cells. 2009;14:79–87. [PubMed]
10. Keren-Paz A, Bercovich Z, Kahana C. Antizyme inhibitor: a defective ornithine decarboxylase or a physiological regulator of polyamine biosynthesis and cellular proliferation. Biochem Soc Trans. 2007;35:311–313. [PubMed]
11. Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR. Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism. J Cell Sci. 2006;119:2583–2591. [PubMed]
12. Kusano T, Berberich T, Tateda C, Takahashi Y. Polyamines: essential factors for growth and survival. Planta. 2008;228:367–381. [PubMed]
13. Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem. 2006;281:14529–14532. [PubMed]
14. Kahana C. Antizyme and antizyme inhibitor, a regulatory tango. Cell Mol Life Sci. 2009;66:2479–2488. [PubMed]
15. Licatalosi DD, Darnell RB. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet. 11:75–87. [PMC free article] [PubMed]
16. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3:285–298. [PubMed]
17. Wang J, Smith PJ, Krainer AR, Zhang MQ. Distribution of SR protein exonic splicing enhancer motifs in human protein-coding genes. Nucleic Acids Res. 2005;33:5053–5062. [PMC free article] [PubMed]
18. Manley JL, Tacke R. SR proteins and splicing control. Genes Dev. 1996;10:1569–1579. [PubMed]
19. Du K, Leu JI, Peng Y, Taub R. Transcriptional up-regulation of the delayed early gene HRS/SRp40 during liver regeneration. Interactions among YY1, GA-binding proteins, and mitogenic signals. J Biol Chem. 1998;273:35208–35215. [PubMed]
20. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, et al. Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology. 2008 [PMC free article] [PubMed]
21. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938–947. [PubMed]
22. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456–467. [PubMed]
23. Mamroud-Kidron E, Omer-Itsicovich M, Bercovich Z, Tobias KE, Rom E, Kahana C. A unified pathway for the degradation of ornithine decarboxylase in reticulocyte lysate requires interaction with the polyamine-induced protein, ornithine decarboxylase antizyme. Eur J Biochem. 1994;226:547–554. [PubMed]
24. Tobias KE, Kahana C. Exposure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. Cell Growth Differ. 1995;6:1279–1285. [PubMed]
25. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003;31:3568–3571. [PMC free article] [PubMed]
26. Pruitt KD, Tatusova T, Maglott DR. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2005;33:D501–504. [PMC free article] [PubMed]
27. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, et al. The sequence of the human genome. Science. 2001;291:1304–1351. [PubMed]
28. Bercovich Z, Kahana C. Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme. J Biol Chem. 2004;279:54097–54102. [PubMed]
29. Guo J, Loke J, Zheng F, Hong F, Yea S, Fukata M, Tarocchi M, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology. 2009;49:960–968. [PMC free article] [PubMed]
30. Guo J, Hong F, Loke J, Yea S, Lim CL, Lee U, Mann D, et al. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem. 2009 [PubMed]
31. Daikuhara Y, Tamada F, Takigawa M, Takeda Y, Mori Y. Changes in polyamine metabolism of rat liver after administration of D-galactosamine. Favorable effects of putrescine administration on galactosamine-induced hepatic injury. Gastroenterology. 1979;77:123–132. [PubMed]
32. Diehl AM, Abdo S, Brown N. Supplemental putrescine reverses ethanol-associated inhibition of liver regeneration. Hepatology. 1990;12:633–637. [PubMed]
33. Wu C, Kennedy DO, Yano Y, Otani S, Matsui-Yuasa I. Thiols and polyamines in the cytoprotective effect of taurine on carbon tetrachloride-induced hepatotoxicity. J Biochem Mol Toxicol. 1999;13:71–76. [PubMed]
34. Casero RA, Jr., Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov. 2007;6:373–390. [PubMed]